Combination therapy with acalabrutinib plus bendamustine and rituxumab showed an overall response rate in excess of 90% of patients with treatment-naïve mantle cell lymphoma and an ORR of 85% in patients with relapsed/refractory disease in an ongoing open-label phase Ib study. The safety profile was consistent with expected safety profiles for acalabrutinib and BR, said Tycel Phillips, MD, who presented the data at the 2018 American Society of Hematology Annual Meeting.